CGEN
Compugen Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.59
+1.37%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 74.0M | 72.8M | 27.9M | 33.5M | 7.5M |
| Cost of Revenue | 9.7M | 9.3M | 7.9M | 2.0M | 975.0K |
| Gross Profit | 64.3M | 63.5M | 19.9M | 31.5M | 6.5M |
| Operating Expenses | |||||
| R&D Expense | 24.6M | 22.8M | 24.8M | 34.5M | 30.6M |
| SG&A Expense | 9.4M | 9.4M | 10.0M | 10.0M | 11.3M |
| General & Admin Expense | 8.8M | 8.9M | 9.4M | 9.7M | 10.3M |
| Selling & Marketing Expense | 572.0K | 539.0K | 576.0K | 244.0K | 932.0K |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 34.0M | 32.2M | 34.8M | 44.4M | 41.9M |
| Cost and Expenses | 43.7M | 41.4M | 42.8M | 46.5M | 42.9M |
| Operating Income (EBIT) | 30.3M | 31.3M | (14.9M) | (13.0M) | (35.4M) |
| Non-Operating | |||||
| Interest Income | 3.4M | 4.4M | 5.2M | 3.2M | 1.4M |
| Interest Expense | — | — | 34.0K | 31.0K | 27.0K |
| Net Interest Income | 3.4M | 4.4M | 5.2M | 3.2M | 1.4M |
| Other Non-Op Income/Expense | 4.9M | 4.1M | 5.2M | 3.2M | 1.7M |
| Non-Operating Income (excl Interest) | (4.9M) | (4.1M) | (5.2M) | (3.2M) | (1.8M) |
| EBT (Pre-Tax Income) | 35.2M | 35.4M | (9.7M) | (9.8M) | (33.6M) |
| Income Tax Expense | 52.0K | 54.0K | 4.5M | 9.0M | 58.0K |
| Bottom Line | |||||
| Net Income | 35.2M | 35.3M | (14.2M) | (18.8M) | (33.7M) |
| Earnings from Cont. Ops | 35.2M | 35.3M | (14.2M) | (18.8M) | (33.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 35.2M | 35.3M | (14.2M) | (18.8M) | (33.7M) |
| Per Share | |||||
| Basic EPS | $0.38 | $0.38 | ($0.16) | ($0.21) | ($0.39) |
| Diluted EPS | $0.38 | $0.38 | ($0.16) | ($0.21) | ($0.39) |
| Revenue Per Share | $0.78 | $0.78 | $0.31 | $0.38 | $0.09 |
| Shares | |||||
| Basic Shares Outstanding | 94.6M | 93.4M | 89.5M | 87.6M | 86.6M |
| Diluted Shares Outstanding | 94.6M | 93.8M | 89.5M | 87.6M | 86.6M |
| Profitability Metrics | |||||
| EBITDA | 35.2M | 35.9M | (9.2M) | (9.3M) | (33.1M) |
| D&A | — | 475.0K | 486.0K | 476.0K | 482.0K |
| EBIT | 35.2M | 35.4M | (9.7M) | (9.8M) | (33.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026